読み込み中
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
前日終値
$19.58
+$0.35 · +1.82%
日中の時刻はETです。市場データは遅延する場合があります。
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
日中レンジ
現在 $19.58
52週レンジ
現在 $19.58
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
48
適正価値
センチメント
66
強気
リスク
26
中程度のリスク
モメンタム
57
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
日中レンジ
現在 $19.58
52週レンジ
現在 $19.58
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1.13億 USD | 1.2億 USD | 1.21億 USD | 1.14億 USD | 1.48億 USD |
| 売上原価 | 4901.2万 USD | 4390.9万 USD | 3826万 USD | 4060.7万 USD | 6485.1万 USD |
| 粗利益 | 6380.7万 USD | 7599.8万 USD | 8253.2万 USD | 7322万 USD | 8294.3万 USD |
| 研究開発 | 2577万 USD | 2554.4万 USD | 2176.3万 USD | 1832.1万 USD | 2732.7万 USD |
| 販売・一般管理 | 4908.8万 USD | 5555.5万 USD | 5992.5万 USD | 5122.9万 USD | 7409.6万 USD |
| 営業費用 | 7485.8万 USD | 8109.9万 USD | 8168.8万 USD | 6955万 USD | 8032.8万 USD |
| 受取利息 | — | — | 231.2万 USD | 65.4万 USD | — |
| 減価償却費と償却費 | 572.9万 USD | 812.1万 USD | 1421.7万 USD | 1448.7万 USD | 1431.7万 USD |
| 営業利益 | −1105.1万 USD | −510.1万 USD | 84.4万 USD | 367万 USD | 261.5万 USD |
| 純利益 | −1088万 USD | −5638.5万 USD | −8266.7万 USD | −1485.9万 USD | 413.4万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI830.26万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM587.76万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF326.1万0.00%954億 USD0.05%$235+0.80%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV293.07万0.01%268.09億 USD0.33%$37.95-0.39%
Fidelity Small-Mid Multifactor ETFFSMD205.61万0.08%24.9億 USD0.15%$49.96+0.48%
Dimensional - US Small Cap ETFDFAS196.68万0.01%338.69億 USD0.31%$78.35+0.32%
Vanguard Russell 2000 ETFVTWO137.64万0.01%180億 USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA133.42万0.01%218.24億 USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFU.S. Small Cap Value Portfolio ETF Class SharesDFSVFidelity Small-Mid Multifactor ETFFSMDDimensional - US Small Cap ETFDFASVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
